{
  "title": "Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.",
  "pmid": "40774040",
  "doi": null,
  "affiliations": [
    "Erasmus MC Cancer Institute, University Medical Center, Rotterdam, the Netherlands. Electronic address: a.dingemans@erasmusmc.nl.",
    "Sotiria General Hospital, Athens, Greece.",
    "Department of Biomedical, Experimental and Clinical Sciences \"Mario Serio\", University of Florence, Florence, Italy.",
    "Centre Hospitalier Universitaire de Liège, Liège, Belgium.",
    "Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.",
    "The Cancer & Hematology Centers of Western Michigan, Grand Rapids, MI, USA.",
    "Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.",
    "Pius-Hospital Oldenburg, Oldenburg, Germany.",
    "Okayama University Hospital, Okayama, Japan.",
    "Hospital Bichat-Claude Bernard, Paris, France.",
    "The Prince Charles Hospital, University of Queensland, Brisbane, Australia.",
    "Rigshospitalet, Copenhagen, Denmark.",
    "Department of Medicine, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.",
    "Oncoclinicas, Rio De Janeiro, Brazil.",
    "Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, United Kingdom.",
    "University Clinical Centre, Medical University of Gdansk, Poland.",
    "SCRI at OHC, Cincinnati, OH, USA.",
    "Amgen Inc., Thousand Oaks, CA, USA.",
    "Amgen Inc., Thousand Oaks, CA, USA.",
    "Lausanne University Hospital, Lausanne, Switzerland."
  ]
}